Population Pharmacokinetics and Exposure‐Response Modeling for Evinacumab in Children, Adolescents, and Adults With Homozygous Familial Hypercholesterolemia [PDF]
CPT: Pharmacometrics and Systems PharmacologyEvinacumab, an angiopoietin‐like 3 (ANGPTL3) inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C), independent of low‐density lipoprotein receptor, in patients with homozygous familial hypercholesterolemia (HoFH).
Lutz Harnisch +2 more
exaly +4 more sources
Management of Familial Hypercholesterolemia with Special Emphasis on Evinacumab
Biomedicines, 2022 Familial hypercholesterolemia (FH) is an underdiagnosed disease that contributes to a significant number of cardiovascular incidents through high serum Low-Density Lipoprotein Cholesterol (LDL-C) values. Its treatment primarily requires healthy lifestyle
Jacek Rysz +2 more
exaly +5 more sources
Comparison of Model‐Predicted and Observed Evinacumab Pharmacokinetics and Efficacy in Children Aged < 5 Years With Homozygous Familial Hypercholesterolemia [PDF]
CPT: Pharmacometrics & Systems PharmacologyEvinacumab, an angiopoietin‐like 3 inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C) in patients with homozygous familial hypercholesterolemia (HoFH).
Sébastien Bihorel +18 more
doaj +3 more sources
Baseline characteristics and response to evinacumab in females and males with homozygous familial hypercholesterolemia in the ELIPSE OLE study [PDF]
American Journal of Preventive CardiologyAim: Evinacumab is an ANGPTL-3 inhibitor developed for the treatment of homozygous familial hypercholesterolemia (HoFH), a rare condition characterized by extremely elevated LDL-cholesterol (LDL-C) levels and premature atherosclerotic cardiovascular ...
Diane Brisson +5 more
doaj +2 more sources
Post-heparin plasma lipase activities in patients with severe hypertriglyceridemia treated with evinacumab [PDF]
Journal of Lipid ResearchPatients with severe hypertriglyceridemia (sHTG) have variable lipoprotein lipase (LPL) activity levels that may influence therapeutic response. This exploratory analysis investigated post-heparin triglyceride lipase and phospholipase activities in three
Cecilia Vitali +5 more
doaj +2 more sources
Pharmaceuticals, 2023 Evinacumab, a human monoclonal antibody against angiopoietin-like protein 3 (ANGPTL3), has recently been approved by the U.S. Food and Drug Administration as an add-on therapy for homozygous familial hypercholesterolemia (HoFH) in patients of 12 years ...
Alessandra Maestro +2 more
exaly +3 more sources
Outpatient monthly plasmapheresis with post-PLEX evinacumab in pediatric homozygous familial hypercholesterolemia: a case report on port access and immunoglobulin preservation [PDF]
Frontiers in PediatricsHomozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by severely elevated low-density lipoprotein (LDL) cholesterol levels, predisposing patients to early cardiovascular disease.
Guido Filler +2 more
doaj +2 more sources
Efficacy of a novel PCSK9 inhibitory peptide alone and with evinacumab in a mouse model of atherosclerosis [PDF]
Journal of Lipid ResearchAtherosclerosis is the major cause of cardiovascular disease. This study evaluated the effect of lipid lowering using a novel peptide inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) and a monoclonal antibody against angiopoietin-like 3 ...
José A. Inia +7 more
doaj +2 more sources
The ANGPTL3-integrin α5 axis drives retinal vascular leakage in diabetic retinopathy [PDF]
Journal of Translational MedicineBackground Breakdown of the blood-retinal barrier (BRB) is a key driver of diabetic retinopathy (DR). While Angiopoietin-like protein 3 (ANGPTL3) is a clinical predictor of DR, its causal role and mechanism in retinal vascular pathology are unknown ...
Jing Ke +6 more
doaj +2 more sources
Effects of Inclisiran, Alirocumab, Evolocumab, and Evinacumab on Lipids: A Network Meta-Analysis [PDF]
Reviews in Cardiovascular MedicineBackground: Direct comparisons between the drugs are limited, and the dosing remains debatable. Therefore, the study aims to indirectly compare the efficacy and safety of inclisiran, alirocumab, evolocumab, and evinacumab in lipid ...
Lin Zhang +5 more
doaj +2 more sources